

152

Atty Dkt. 246102002700
Client: 157 App 3 1992
PATENT



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on March 13, 1992

Mar. 13, 1992
Date

Marilyn B. McKenna
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

CHRIS BUHR et al.

Serial No.: 07/652,978

Group Art Unit: 187 Y 804

Filing Date: 8 February 1991

Examiner: Unassigned

Title: METHYLENE PHOSPHONATE
OLIGONUCLEOTIDE ANALOGS
AND NUCLEOSIDES

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.99

The Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

The information listed below, which may be material to the examination of the above-identified application, was disclosed to the Examiner at pages 2-4 of the application as originally filed. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

Uhlmann et al., Chemical Reviews (1990) 90:543-584; —

Frick et al., Meeting Abstract, Conference on Nucleic Acid Therapeutics, January 13-17, 1991, Clearwater Beach, Florida, p. 63; and

Ikehara et al., Heterocycles (1984) 21:75-90. ✓

The references above are summarized on pages 2-4 of the application as originally filed. The summaries contain what the undersigned believes to be the salient aspects of the cited references. They are not intended to be a comprehensive statement of the relevance of the references to the subject invention. Accordingly, the references may contain information not mentioned in the summaries that the Examiner might consider material and the Examiner is thus urged to review the references and to draw his or her own conclusions as to their materiality and relevancy.


Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 CFR § 1.99 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties

are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By:


Nancy Joyce Gracey
Registration No. 28,216

MORRISON & FOERSTER
545 Middlefield Road, Suite 200
Menlo Park, California 94025
Telephone: (415) 813-5600
Fax: (415) 327-2951